AU: ACCC targets alleged false and misleading Nurofen claims

30 March 2015

The Australian Competition and Consumer Commission (ACCC) has instituted proceedings in the Federal Court of Australia against Reckitt Benckiser (Australia) Pty Ltd (Reckitt Benckiser), alleging that it made false or misleading claims that its Nurofen Specific Pain Products were each formulated to treat a specific kind of pain, when the products are identical and each contain the same active ingredient, ibuprofen lysine 342mg.
The ACCC is seeking declarations, injunctions, an order for the publication of corrective notices, penalties and costs. This matter is listed for a case management conference on 31 March 2015 in the Federal Court of Australia in Sydney (ACCC Media Release, 5 March 2015).
Click here for the full media release.
Click here for more information about Pharmaceutical packaging regulations - Module of NVC E-Course Pharmaceutical Packaging (online).

If you have any questions about this subject, please contact us:, +31-(0)182-512411. This item is also included in our monthly overview, the NVC Members-only Update.